



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Renu Wadhwa et al. Art Unit : 1644
Serial No. : 10/725,906 Examiner : Michail A. Belyavskiy
Filed : December 1, 2003
Title : PROTEIN AND GENE INVOLVED IN MYOCYTE DIFFERENTIATION

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached forms PTO-1449. Under 37 C.F.R. § 1.98(a)(2)(ii), only copies of non-patent literature are enclosed. Some of these references were previously cited in an Information Disclosure Statement filed December 1, 2003. Under 37 C.F.R. § 1.98(d), these references were not submitted, since they were previously submitted in an earlier application. For the Examiner's convenience, the references are submitted herein.

This application is a divisional application of Serial No. 09/684,579, now issued as U.S. Patent No. 6,670,450. Applicants wish to bring to the Examiner's attention co-pending Non-Provisional Application 10/725,876, filed December 1, 2003, which is also a divisional of 09/684,579.

11/01/2005 EAREGAY1 00000032 10725906

01 FC:1806

180.00 OP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

10/28/05

Signature

Typed or Printed Name of Person Signing Certificate

Sally Hammer

Applicant : Renu Wadhwa et al.
Serial No. : 10/725,876
Filed : December 1, 2003
Page : 2 of 2


Attorney's Docket No.: 14875-066003 / C2-903PCT-
USD2

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action. A check for \$180 in payment of the late submission fee of § 1.17(p) is enclosed. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket Number 14875-066003.

Respectfully submitted,

Date:

Oct. 28, 2005


Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney's Docket No.

14875-066003

Application No.

10/725,876

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

Applicant

Renu Wadhwa et al.

Filing Date

December 1, 2003

Group Art Unit

1644

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,458,533	10/01/2002	Felder et al.	435	6	12/22/1998
	AB						
	AC						
	AD						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE							
	AF							
	AG							
	AH							
	AI							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AJ	Attwood T.K., "The Babel of Bioinformatics" Science, 290 (5491): 471 (2000)
	AK	Branch A.D. "A good antisense molecule is hard to find" Trends Biochem. Sci., 23(2): 45 - 50 (1998)
	AL	Burgess, W.H. et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" Jour. Cell Biol., 111:2129-2138 (1990)
	AM	Lazar E., et al., "Transforming Growth Factor α Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" Mol. Cell. Biol., 8 (3): 1247-1252 (1998)
	AN	Mountain A., "Gene therapy: the first decade" Trends in Biotechnol., 18(3):119-128 (2000)
	AO	Skolnick J. et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era" Trends in Biotechnol., 18(1):34-39 (2000)
	AP	
	AQ	
	AR	
	AS	

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.